Navigation Links
Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Date:3/13/2008

2,254 7,408

Commitments

Stockholders' equity:

Preferred stock, $0.00004 par value;

10,000 shares authorized; no shares issued

and outstanding - -

Common stock, $0.00004 par value; 150,000

shares authorized; 40,778 and 31,419 shares

issued and outstanding at December 31,

2007 and December 31, 2006, respectively 2 1

Additional paid-in capital 184,014 163,482

Stock subscription receivables - (27)

Accumulated other comprehensive income 5,895 5,869

Accumulated deficit (164,933) (144,807)

Total stockholders equity 24,978 24,518

Total liabilities and stockholders' equity $56,252 $51,172

Micromet, Inc.

Condensed Consolidated Statements of Operations

(In thousands, except per share amounts)

Three Months Ended Year Ended

December 31, December 31,

2007 2006 2007 2006

Revenues

Collaboration agreements $6,751 $12,596 $17,366 $25,449

License fees and other 234 1,211 1,018 2,134

Total revenues 6,985 13,807 18,384 27,583

Operating expenses

Research and development 9,471 7,385 29,191 28,252

In-process research and

development - - - 20,890

General and administrative 3,590 3,495 14,430 12,012

Total operating expenses 13,061 10,880 43,621
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
2. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
3. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
4. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
5. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
6. Helix BioPharma reports Q2 2008 highlights, financial results
7. Oncothyreon reports full year and fourth quarter 2007 financial results
8. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
9. Alfacell Reports Financial Results for Second Quarter of Fiscal 2008
10. ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
11. Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... , July 6, 2015 ImmunoCellular Therapeutics, ... of an agreement with Novella Clinical (Novella), ... in patients with newly diagnosed glioblastoma. Novella is a ... services to small to mid-sized oncology companies. The ICT-107 ... in the US, Europe and ...
(Date:7/3/2015)... ... ... global failure analysis market is expected to reach $7,147.0 million by 2020, at a ... at the highest CAGR of 8.46%; its growth is expected to be driven by ... for root cause analysis of failure. The market based on the geographic regions has ...
(Date:7/2/2015)... , ... July 03, 2015 , ... Cuvettes have been used in countless labs for ... to find the cuvette they needed. As expected, this was a daunting and tiring ... wrong part because they were not able to navigate the complex catalog structure. , Now ...
(Date:7/2/2015)... ... 02, 2015 , ... In’Tech Medical SAS ( http://www.intech-medical.com ), ... today the acquisition of Turner Medical, Inc ., thus becoming a global ... the Spine Industry. The acquisition of Turner Medical ideally supplements In’Tech Medical’s product ...
Breaking Biology Technology:ImmunoCellular Therapeutics Establishes Agreement with Novella Clinical to Conduct ICT-107 Phase 3 Registration Trial in Glioblastoma 2Failure Analysis Market to Grow at 7.52% CAGR to 2020 2Failure Analysis Market to Grow at 7.52% CAGR to 2020 3Failure Analysis Market to Grow at 7.52% CAGR to 2020 4Failure Analysis Market to Grow at 7.52% CAGR to 2020 5New Cuvette E-Commerce Website Launched by FireflySci 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 3
... efforts of two kinds of bacteria to produce hydrogen in ... the other. According to an article in the August issue ... bonus: leftover enzymes can be used to scavenge precious metals ... convert hydrogen into energy. , Hydrogen has three times more ...
... 6, 2008 TIME: 9:30 ... Dr. Candace Kendle, Chairman and CEO, Kendle (Nasdaq: KNDL ... Aug. 6 at 9:30 a.m. Eastern Time to,discuss its financial results ... session will follow., Webcast Instructions, To access the live ...
... (Nasdaq: SGMO ) today announced that the company ... July 23,2008, after the market closes. The press release ... PT, which will be open to the public via,telephone ... review,the financial results and discuss other business matters., ...
Cached Biology Technology:Fuel from food waste: bacteria provide power 2Kendle Invites You to Attend its Second Quarter 2008 Earnings Conference Call and Webcast 2Sangamo BioSciences Announces Second Quarter Conference Call and Webcast 2Sangamo BioSciences Announces Second Quarter Conference Call and Webcast 3
(Date:6/25/2015)... 2015 According to a ... & Area), Technology, Material (Optical Prism, Piezoelectric, Capacitive ... & Others) & Geography - Global Forecast to ... market is expected to reach $14,500.07 Million by ... Browse 76 market Tables and 109 Figures ...
(Date:6/24/2015)... The biologics safety testing market is growing ... market include growth of the pharmaceutical and biological industries ... the years, the number of drug approvals in North ... FDA approved 225 drug applications and Health Canada approved ... accounted for 3,822 of the pharmaceutical and ...
(Date:6/24/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/hhwlfj/huawei_ascend ... "Huawei Ascend Mate 7 Fingerprint Sensor - Reverse ... Huawei,s technological choice for the fingerprint sensor ... and Samsung,s one. The Ascend Mate 7 presents ... a main actor in capacitive sensing human interface ...
Breaking Biology News(10 mins):Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2
... 2013 -- A test that measures the expression levels ... effectively differentiate between patients who are at higher and ... the body more than five years after diagnosis, researchers ... individual risk prediction for women with these cancers is ...
... have been bombarded by stories in the media and on ... levels, and urging high doses of supplements to protect against ... But new research from Johns Hopkins finds that blood ... of the range suggested by the Institute of Medicine confer ...
... experimental drug has shown promise in treating influenza, preventing lung ... to University of Maryland School of Medicine researchers publishing in ... found that a drug called Eritoran can protect mice from ... of influenza virus. The potential value of this drug as ...
Cached Biology News:Gene expression test distinguishes btw breast cancer patients at high & low risk of late recurrence 2Gene expression test distinguishes btw breast cancer patients at high & low risk of late recurrence 3Vitamin D: More may not be better 2University of Maryland School of Medicine researchers find potential novel treatment for influenza 2
... sets a new standard for high performance ... new design in instrumentation, this easy-to-use benchtop ... The BD FACSAria instrument is the first ... flow cell. This new flow cell ...
Mouse polyclonal antibody raised against a partial recombinant IFNA13. NCBI Entrez Gene ID = 3447...
Mouse polyclonal antibody raised against a partial recombinant NCLN. NCBI Entrez Gene ID = 56926...
...
Biology Products: